CBRE Group CBRE
Real Estate · Real Estate - Services · Synthos Deep Dive · 2026-07-03
The Overview
CBRE is the biggest company in the world at helping other people buy, sell, lease, and run commercial buildings — offices, warehouses, malls, data centers. It earns fees and commissions when deals happen and steady management fees for running buildings day-to-day. Think of it as the giant real-estate agency and building-manager for big corporations and landlords.
Here's the thing to understand: its profits go up and down with the economy and with interest rates. When rates spiked, property deals froze and CBRE's earnings dropped; now deals are thawing and earnings are climbing back. So a lot of the "growth" you'll hear about is really a recovery from a bad patch, not a brand-new engine.
The stock is not expensive — you're paying a fair price, roughly in line with the company's history. Our verdict is Watch: it's a solid, well-run business, but nothing in our research gives us an edge to say "buy now," and its profits are wobbly by nature. The stock has actually gone nowhere for a year while the market rose ~20%.
What the three scores mean in everyday words:
- Downside Risk 5/10 (middle). The price is fair and the company is a survivor, but its earnings swing hard with the economy and it carries a fair bit of debt.
- Growth Quality 6/10 (decent). It should grow earnings at a good clip for a few years — but it keeps only about 3 cents of profit per sales dollar, so it's a thin-margin business, not a money machine.
- Exponential Potential 3/10 (low). It's already the biggest fish in its pond, in a slow-changing industry. Don't expect it to multiply.
The one big worry: its whole business rides on interest rates and the property cycle. If rates stay high or a recession hits, deal activity dries up and earnings fall fast.
Putting a number on it: our fair-value estimate is $165 against a current price of $150.87 — real upside if our numbers are right.
Our summary metrics
Reasonable ~18× forward EPS & sturdy franchise, but deeply cyclical, rate-sensitive, net-debt/EBITDA 2.3×, below its 200-DMA.
~15% forward adj-EPS CAGR off a cyclical trough, but thin 3% net margins & modest ~6% ROIC cap the quality.
Cyclical recovery, not secular acceleration; already the scale leader in a mature industry, and AI is a threat here, not a tailwind.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Cyclical recovery, not secular acceleration; already the scale leader in a mature industry, and AI is a threat here, not a tailwind.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $178 (high $185 / low $169; 13 Buy · 6 Hold · 1 Sell) — context, not our anchor |
| Valuation | 32× trailing GAAP EPS · ~18× FY26E adj · ~16× FY27E adj · ~11× FY30E adj · EV/S 1.1× · EV/EBITDA 17.8× |
| Technicals | Weak/neutral — $141.6, −17.5% off 52-wk high, below the 200-DMA ($150), flat 12-mo (SPY +21%), RSI 67 |
| Conviction | Low — 0 net-bullish voices; the single loudest KB claim is a bearish AI-disruption thesis (conviction 70) |
| Position sizing | Watch-list / small tactical only, ≤1–2% if bought at all |
What the experts actually said 3 traceable claims on CBRE · showing the highest-conviction voices
“Credit-exposed names (KKR, CBRE, Ares, Huntington) plus Campbell Soup are the worst breakdowns on the negative-momentum list right now.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $150.82, 5% above the 50-day average ($143), 2% above the 200-day average ($147) — an uptrend. 12% below the 52-week high of $172, 21% above the 52-week low of $125.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $150.82 is currently inside the band (band $145–$155).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 55.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.49, negative momentum.
Relative performance vs S&P 500 & its sector (XLRE (sector)), set to 100 a year ago
Solid = CBRE · dashed = S&P 500 · dotted = XLRE (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
CBRE Group (NYSE: CBRE), founded 1906, headquartered in Dallas, is the world's largest commercial real estate (CRE) services and investment firm — ~155,000 employees. It makes money three ways: transactional advisory (leasing and property-sales brokerage, mortgage origination, valuation), recurring outsourcing (facilities and project management — the Turner & Townsend and integrated-workplace businesses), and real-estate investment management/development (CBRE Investment Management, Trammell Crow). Fiscal year ends December 31.
In 2025 CBRE reorganized its reporting segments. The current structure:
- Advisory Services — the classic brokerage engine (leasing, capital markets/sales, mortgage, valuation). The most cyclical, highest-margin part.
- Building Operations & Experience and Project Management (incl. Turner & Townsend) — recurring, contractual facilities/project management; lower margin but far more stable.
- Real Estate Investments — investment management (fee streams on AUM) plus development.
Revenue mix — a critical nuance. FMP reports two different views because of the 2025 restructuring, and the "net revenue" segment view understates the gross-up:
- FY2025 net-revenue segments (FMP): Advisory Services $8.84B · Project Management $7.66B · Real Estate Investments $0.88B. These sum to ~$17.4B of net revenue; the gap to the $40.55B total gross revenue is the pass-through cost of managed facilities (staff, subcontractors billed through at low margin). This is why CBRE's reported gross revenue is huge but net margins are thin (~3%): a large slice of "revenue" is reimbursed cost.
- By geography (FY2025): United States $22.85B (56%) · United Kingdom $5.71B (14%) · all other countries $11.99B (30%). US-led but genuinely global — a strength (diversification) and a currency/macro exposure.
The most important thing to internalize: the advisory/capital-markets engine is a leveraged bet on the property transaction cycle, while the outsourcing book is a ballast of recurring fees. The current recovery story is the advisory engine thawing as rates normalize.
2. The expert thesis — what the panel actually says (traceable)
There is no net-bullish expert coverage of CBRE in the Synthos knowledge base. Breadth is 0 net-bullish voices; the file contains 4 total claims, and the single distilled top voice is cautionary/bearish. This verdict is therefore fundamentals- and quant-driven, not conviction-driven — and honesty demands we say so up front.
The one voice on record is a bear:
- Compound & Friends (
compound_and_friends-LaCVAk3gSEc:595de9c551, bearish, conviction 70, skill 1.0, dated 2026-05-03): "CRE brokerage's information-asymmetry edge gets eroded as AI-armed amateurs gain pricing/supply knowledge; not a Halo business." The thesis: CBRE's franchise historically rested on knowing more about pricing, supply, and comps than the counterparty — and generative AI plus open data commoditizes exactly that edge. It explicitly denies CBRE is a durable "Halo" (structurally advantaged) business.
Honest read. We do not treat one bearish claim as dispositive — brokerage is also about relationships, execution, capital access, and scale that AI does not replicate overnight. But the absence of any offsetting bullish expert, combined with a credible disruption thesis from a skilled voice, is a real signal: nobody in our panel is banging the table for CBRE, and the loudest voice is arguing the moat is eroding. That is the opposite of the LLY-style conviction stack, and it is why CBRE lands on the Watch list rather than in a Buy sleeve.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics:
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Forward valuation is reasonable (~18× FY26E adj EPS, EV/S 1.1×) and the franchise is durable, but net-debt/EBITDA 2.3×, beta 1.22, deep cyclicality, and a chart below its 200-DMA offset the fair price. |
| Growth Quality | 6 · Decent | ~15% forward adjusted-EPS CAGR and ~9% revenue CAGR, but off a cyclical trough; 3.1% net margin, ~6% ROIC, ~15% ROE — a scale leader, but a thin-margin, capital-modest one. |
| Exponential Potential | 3 · Low | A cyclical earnings recovery, not secular acceleration. Already the #1 player in a mature, fragmented industry; AI is a threat to the core edge, not a tailwind. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, and the cases bound the range. All EPS below are on the adjusted/"core" basis that the Street estimates use — note GAAP EPS runs lower (FY25 GAAP diluted EPS was $3.85 vs ~$7.1 adjusted).
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Rates fall, capital-markets/leasing volumes snap back hard, Turner & Townsend + data-center development compound; FY27E adj EPS beats to ~$9.50 (vs $8.88 cons); cycle-peak multiple ~22×. | ~$210 (+48%) |
| Base (our anchor) | Estimates roughly hit — FY27E adj EPS ~$8.88; a durable mid-cycle compounder earns a ~18–19× multiple. | ~$165 (+17%) |
| Bear | Rates stay high or a recession hits; transaction volumes re-freeze, capital-markets revenue rolls over; FY27E adj EPS misses to ~$7.50; multiple de-rates to cyclical-trough ~15×. | ~$110 (−22%) |
Synthos fair value = the base case, ~$165 (+17%), with the full $110–$210 span as the honest range. This anchor sits below the Street's $178 consensus — we discount the Street's optimism because the "growth" is a rate-dependent recovery and one skilled voice argues the moat is eroding. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). CBRE is neither a high-return compounder nor an exponential — it is a cyclical scale leader:
- Forward growth: revenue CAGR FY25→FY30E ~8.8% ($40.6B → $61.8B); adjusted-EPS CAGR FY26E→FY30E ~14.6% ($7.72 → $13.35). Respectable, but the EPS growth is amplified by (a) recovering off a rate-shocked trough and (b) buybacks (share count down from ~336M in 2020 to ~296M now).
- Acceleration (2nd derivative): the near-term EPS jump is cyclical recovery — FY25 adj ~$6.3 → FY26E $7.72 (+22%) → FY27E $8.88 (+15%) → FY28E $10.09 (+14%) → FY30E $13.35. Growth decelerates as the recovery matures; this is a mean-reversion ramp, not a compounding secular curve.
- Room to run: the global CRE services TAM is large and fragmented, but CBRE is already the biggest player in it. It gains share slowly; it does not open new trillion-dollar markets. At $41.5B it is not capacity-constrained on TAM, but the nature of the industry (mature, commoditizing, low-margin) caps the multiple of the multiple.
- The AI wrinkle: for most names AI is optionality. Here the KB's only voice argues AI is a headwind — commoditizing the information edge (
compound_and_friends-LaCVAk3gSEc:595de9c551). Even discounting that, AI is at best neutral for CBRE, not an exponential accelerant.
Exponential Potential: Low (3/10). Own CBRE, if at all, as a cyclical value/quality-at-a-fair-price holding tied to the rate/property cycle — not as a growth compounder and certainly not as a multibagger.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $40.55B, +13.4% (FY24 $35.77B, +12% on FY23 $31.95B). Solid gross-revenue growth, but remember much is low-margin pass-through.
- Quarterly trajectory: Q1'25 $8.91B → Q2 $9.75B → Q3 $10.26B → Q4 $11.63B → Q1'26 $10.53B (+18% YoY). Momentum is real and improving as advisory recovers.
- Margins (the honest tell): gross 35.0% TTM, EBITDA margin only 6.4%, operating ~3.8%, net just 3.1% TTM. Thin by design — the facilities-management gross-up dilutes reported margins. Net income FY25 $1.16B (GAAP), up from $968M FY24.
- EPS: FY25 GAAP diluted $3.85 (vs $3.14 FY24). Adjusted/core (the basis analysts quote and CBRE guides to) runs materially higher, ~$7.1 TTM — the gap is amortization of acquired intangibles, integration costs, and carried-interest timing. Always check which EPS is quoted.
- Returns on capital: ROE 15.4%, but ROIC only 5.9% and ROA 4.3% — the acquisition-heavy, goodwill-laden balance sheet ($7.1B goodwill + $3.0B intangibles = ~1/3 of assets) dilutes returns.
- Cash flow: FY25 operating CF $1.56B, capex −$366M, FCF $1.19B. FCF is lumpy (was just $229M in 2023, $1.49B in 2024) — working-capital swings in a brokerage make FCF noisy quarter to quarter.
- Balance sheet: total debt $9.99B, net debt $8.13B, net-debt/EBITDA 2.3× — up sharply from ~1.6× a year ago as CBRE levered up for the Turner & Townsend combination and other M&A. Investment-grade and serviceable (interest coverage ~8×), but leverage is now a watch item, not a non-issue.
6. Valuation — priced in or room?
Unlike the megacap-growth names, CBRE is not obviously expensive:
- Trailing: 32× GAAP EPS looks high, but on adjusted EPS (~$7.1 TTM) it's ~20×; EV/EBITDA 17.8×, EV/Sales just 1.1×, P/S ~1.0×, P/B 4.9×.
- Forward (adjusted, the fair basis): ~18× FY26E ($7.72) → ~16× FY27E ($8.88) → ~11× FY30E ($13.35). For a franchise growing adjusted EPS mid-teens, ~18× forward is reasonable, not cheap and not rich — roughly in line with CBRE's own multi-year history.
- The catch: that forward multiple is only "cheap" if the cyclical recovery in estimates actually lands. If rates stay high, the E in P/E falls and the "cheap" multiple was a mirage. This is the classic cyclical-value trap risk.
- Reverse read: at $141.6 the market is paying ~18× a recovering earnings stream — pricing in the thaw but not a boom. Not demanding.
- Street targets (context): consensus $178, high $185, low $169; 13 Buy / 6 Hold / 1 Sell; FMP letter rating B (weak on P/E and debt-to-equity sub-scores). Our $165 base sits below consensus — we haircut the Street for cyclicality and the absence of any bullish expert edge.
Bottom line: a fairly-priced cyclical, not a bargain and not a bubble. The valuation supports a Watch, not an Avoid — but it isn't cheap enough to override the lack of a positive edge.
7. Technicals (from the tech block)
- Trend: weak/neutral. $141.58 sits above the 50-DMA ($136) but BELOW the 200-DMA ($150) — a death-cross posture (50 < 200). Not a healthy uptrend.
- Location: −17.5% off the 52-week high ($171.6), +13.6% off the 52-week low ($124.6). Max drawdown from peak −17.5%. The stock is in a corrective phase.
- Momentum: RSI(14) 67 — approaching overbought on the recent bounce, MACD mildly positive (+1.06). The near-term bounce is real but into resistance (the 200-DMA overhead).
- Relative strength (the tell): CBRE is −0.03% over 12 months vs SPY +20.6% and QQQ +30.3% — dramatic underperformance. Even over 3 months (+5.3%) it lags SPY (+13.7%) and QQQ (+22%). 6-month return is −13.3%.
- Read: technicals do not confirm a bull case. A name flat for a year while the market ran 20%, trading below its 200-DMA, is not showing the leadership you'd want before adding. A reclaim of the 200-DMA (~$150) on volume would be the technical green light; until then this is a "prove it" chart.
8. Moat & competitive position
CBRE's moat is scale and breadth, not a structural information monopoly. As the largest CRE services firm, it wins large-corporate outsourcing mandates that smaller rivals can't staff globally, cross-sells advisory into managed accounts, and deploys capital (loans, co-investment) that levers relationships. The recurring facilities/project-management book (Turner & Townsend) adds ballast and is genuinely sticky.
But the moat has real limits: brokerage is fragmented and commoditizing; switching costs on transactional advisory are low; and the KB's one voice argues AI erodes the pricing/supply information edge that historically justified fees (compound_and_friends-LaCVAk3gSEc:595de9c551). ROIC of ~6% is the quantitative fingerprint of a decent but not fortress moat.
Peer set (FMP, market cap): direct services comp JLL $15.2B (Jones Lang LaSalle) — CBRE is ~2.7× its size; data/tech-adjacent CoStar $12.3B and KE Holdings $16.1B; and REIT/infra names FMP lists as peers but which are not true operating comps — Simon Property $73B, Digital Realty $61B, Realty Income $60B, Public Storage $58B, Crown Castle $33B. The only clean operating peer is JLL; CBRE is the scale leader of the two-firm advisory oligopoly at the top, with a long tail of regional brokers below.
9. Management, capital allocation & guidance
- Leadership: CEO Robert E. Sulentic (long-tenured). The 2025 segment reorganization and the Turner & Townsend combination reflect a deliberate tilt toward recurring, less-cyclical revenue — strategically sensible given the cyclicality critique.
- Capital allocation: no dividend (yield 0%); capital returns come via buybacks — $968M repurchased in FY25, and share count has fallen from ~336M (2020) to ~296M (Q1'26), a real ~12% reduction. Offset: M&A-driven leverage rose to net-debt/EBITDA 2.3×, and goodwill+intangibles are ~1/3 of assets. Buybacks at a fair multiple are fine; the leverage step-up deserves monitoring.
- Insider activity: recent Form 4s (May 2026) are routine director equity awards and gifts (e.g. Yajnik, Boze, Cobert) plus a new officer's Form 3 — no cluster of alarming open-market discretionary selling in the sampled window. Neutral.
- Management's own guidance: not available from our free SEC route. The latest 8-K (2026-04-23, Item 2.02) only furnishes the Q1'26 earnings press release as Exhibit 99.1 and contains no forward revenue/outlook language in the machine-readable cover text. Per house standard we do not fabricate guidance — CBRE does issue full-year "core EPS" guidance on its calls, but we can't quote a dated figure we haven't verified. Treat the Street's FY26E adj EPS ~$7.72 as the consensus proxy, not as management's own words.
10. Catalysts & what to watch
- Next earnings: 2026-07-29 (Q2'26; Street EPS $1.49, revenue ~$11.2B). Key lines: capital-markets (property sales) and leasing revenue growth — the direct read on the transaction-cycle thaw — plus any update to full-year core-EPS guidance.
- Interest-rate path: the single biggest external swing factor. Falling rates → deal volumes recover → advisory earnings inflect up. Sticky-high rates → the recovery stalls and estimates come down.
- Capital-markets / leasing volumes: watch sequential and YoY growth in the Advisory segment specifically.
- Data-center & development pipeline: Trammell Crow / CBRE Investment Management exposure to data-center and industrial development is a genuine secular tailwind embedded in a cyclical business.
- Leverage: whether net-debt/EBITDA trends back toward ~1.5× or stays elevated after M&A.
Thesis tripwires (what would change the call): a re-freeze in capital-markets volume for two consecutive quarters; a cut to full-year core-EPS guidance; net-debt/EBITDA rising above ~2.75×; or corroborating evidence for the AI-disruption bear thesis (fee compression in brokerage).
11. Key risks
- Cyclicality (structural, the #1 risk): advisory/capital-markets earnings are hostage to interest rates and transaction volumes. A recession or sustained high rates hits the highest-margin revenue hardest. Beta 1.22 quantifies the sensitivity.
- AI / moat erosion (the KB bear):
compound_and_friends-LaCVAk3gSEc:595de9c551— AI-armed counterparties commoditize the information edge; potential long-run fee compression. Credible, skilled, and the only distilled voice on the name. - Leverage: net-debt/EBITDA up to 2.3× post-M&A; a downturn plus leverage is a worse combination than either alone.
- Thin margins: 3% net margin leaves little cushion; cost overruns in the managed-services book bite.
- No expert edge: zero net-bullish voices in the KB. We have no informational advantage here — the call rests purely on fair-value quant, which is a weaker foundation than a conviction stack.
- Below 200-DMA / relative underperformance: the price action is not confirming; flat for a year vs a +20% market.
12. Verdict, position sizing & monitoring
Watch. CBRE is a well-run, dominant, fairly-priced franchise — ~18× forward adjusted EPS for a mid-teens EPS grower is not demanding, and the base case offers a modest ~+17% to ~$165. But three things keep it off the Buy list: (1) the "growth" is a rate-dependent cyclical recovery, not a durable secular ramp; (2) there is no net-bullish expert support in our KB, and the only distilled voice is a credible AI-disruption bear; and (3) the price action is weak — flat for a year, below its 200-DMA, badly lagging the market. Fair value plus no edge plus a soft chart equals Watch, not Buy.
- Sizing: if owned at all, ≤1–2% as a tactical, cycle-timed position — ideally added on a reclaim of the 200-DMA (~$150) or on clear evidence rates are falling and capital-markets volumes are inflecting. This is not a core compounder.
- Upgrade triggers (what turns this into a Buy): a durable rate-cut cycle with capital-markets volumes inflecting; a reclaim of the 200-DMA on volume; management raising core-EPS guidance; or a net-bullish expert thesis entering the KB. Downgrade to Avoid if the AI-disruption/fee-compression evidence mounts or leverage climbs into a downturn.
- Monitoring: re-score each earnings print, starting 2026-07-29. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $141.58.
- Single biggest risk: the property-transaction cycle — CBRE's earnings live and die by interest rates and deal volumes.
Provenance & disclosures
- Traceability: 4 KB claims, breadth 0 net-bullish voices, net conviction −70 (the lone distilled voice is bearish,
compound_and_friends-LaCVAk3gSEc:595de9c551, dated 2026-05-03) — reconciled to a realclaim_id. Fabricated conviction is structurally impossible (claim-ID reconciliation). This is a fundamentals/quant-driven note, not a conviction call. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · expert claims through 2026-05-03. Forward figures are analyst consensus (FMP), labeled as estimates. Note the GAAP-vs-adjusted EPS gap — Street estimates and valuation multiples here use adjusted/core EPS.
- Guidance caveat: management's own dated forward guidance was not available from the free SEC 8-K route (the latest 8-K furnishes only the earnings-release exhibit, no machine-readable outlook). We did not fabricate it.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").